Ionis Pharmaceuticals, Inc.
IONS
$75.83
$0.450.60%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 86.98% | -10.26% | 17.12% | 100.69% | 10.14% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 86.98% | -10.26% | 17.12% | 100.69% | 10.14% |
| Cost of Revenue | 5.41% | 15.35% | -0.34% | -2.04% | -6.54% |
| Gross Profit | 146.64% | -270.53% | 27.17% | 23,662.17% | 27.11% |
| SG&A Expenses | 97.19% | 47.81% | 57.06% | 39.18% | 44.84% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 30.54% | 23.83% | 12.19% | 7.17% | 3.52% |
| Operating Income | 20.04% | -93.51% | -7.75% | 311.55% | 1.77% |
| Income Before Tax | 37.13% | -112.93% | 10.90% | 286.60% | -2.87% |
| Income Tax Expenses | 87.93% | 154.94% | 105.88% | -131.25% | 54.67% |
| Earnings from Continuing Operations | 37.03% | -119.83% | 8.45% | 286.45% | -2.90% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 37.03% | -119.83% | 8.45% | 286.45% | -2.90% |
| EBIT | 20.04% | -93.51% | -7.75% | 311.55% | 1.77% |
| EBITDA | 21.23% | -94.74% | -7.98% | 326.46% | 1.56% |
| EPS Basic | 39.38% | -114.42% | 14.85% | 271.01% | 5.66% |
| Normalized Basic EPS | 23.54% | -98.23% | -1.56% | 307.64% | 8.57% |
| EPS Diluted | 39.38% | -114.42% | 14.85% | 254.19% | 5.66% |
| Normalized Diluted EPS | 23.54% | -98.23% | -1.56% | 281.22% | 8.57% |
| Average Basic Shares Outstanding | 3.87% | 2.53% | 7.52% | 9.03% | 9.07% |
| Average Diluted Shares Outstanding | 3.87% | 2.53% | 7.52% | 24.92% | 9.07% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |